ITEM 7.01 REGULATION FD DISCLOSURE
On September 12, 2022, Zymeworks Inc. (“Zymeworks”) issued a press release
announcing that it presented preliminary results from Zymeworks’ Phase 1
clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of
On September 12, 2022, Zymeworks filed this press release with the Canadian
securities regulatory authorities on the System for Electronic Document Analysis
and Retrieval at http://www.sedar.com.
A copy of this press release is attached as Exhibit 99.1 hereto.
The information under this Item 7.01 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”), or otherwise subject to the liability of that section, nor
shall such information be deemed incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, as amended, regardless of the
general incorporation language of such filing, except as shall be expressly set
forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits Exhibit No. Description 99.1 Press Release dated September 12, 2022. 104 Cover Page Interactive Data File (embedded as Inline XBRL document).
© Edgar Online, source Glimpses